Sporadic inclusion-body myositis (s-IBM) is a progressive, highly debilitating, and the most common muscle disease of older persons (over age 60). An intriguing aspect of s-IBM is that its muscle fiber phenotype has features remarkably similar to those of Alzheimer Disease (AD) brain (""""""""IBM-AD phenotype""""""""), including abnormal accumulations of: beta-amyloid precursor protein (betaAPP) and of several other proteins accumulated in AD brain. Another similarity to AD is the presence of hereditary forms, termed """"""""hereditary inclusion-body myopathies (h-IBM)"""""""", which clinically are manifest earlier than s-IBM, but have a muscle- fiber phenotype identical to, though apparently somewhat less advanced than, that of s-IBM. Similarly to AD brain, abnormal muscle fibers of s- and h-IBM muscle, in vivo and in vitro. Therefore, we propose that betaAPP over-expression (whole molecule and/or Abeta fragment in the milieu of aged (s-IBM) or genetically-abnormal adult (h-IBM) muscle fibers causes molecular disturbances leading to the IBM-specific vacuolar muscle-fiber degeneration and expression of the IBM-AD phenotype. This proposal addresses the schedule, and therefore the possible mechanisms, of the early steps in the pathogenic cascade. It involves: 1) three long-term in vitro models, namely, a) spontaneous model utilizing cultures of s-IBM muscle; and cc) an induced model utilizing matured cultured normal human muscle fibers into which is transferred the betaAPP gene; and 2) an induced in vivo aged-rat model based on transfer of the betaAPP gene into aged-rat gastrocnemius muscle. Anti-oxidant treatments, including estrogens, will be done on abnormal cultures. We postulate that in vivo aging of the involve tissues may be a predisposing factor(s) in both the AD group and the IBM's, especially in the sporadic, more common, forms of each. Because our type of cultured spontaneous and induced models of the human tissue actually affected in the patient are not available to study brain involvement in the AD's, possibly our results may provide otherwise- unavailable information relevant to the pathogenesis and treatment of the AD's.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
3P50AG005142-16S1
Application #
6295391
Study Section
Project Start
1999-04-01
Project End
2000-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
16
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Southern California
Department
Type
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Gahm, Jin Kyu; Shi, Yonggang; Alzheimer’s Disease Neuroimaging Initiative (2018) Riemannian metric optimization on surfaces (RMOS) for intrinsic brain mapping in the Laplace-Beltrami embedding space. Med Image Anal 46:189-201
Emrani, Sheina; Libon, David J; Lamar, Melissa et al. (2018) Assessing Working Memory in Mild Cognitive Impairment with Serial Order Recall. J Alzheimers Dis 61:917-928
Hernandez, Gerson; Zhao, Liqin; Franke, Adrian A et al. (2018) Pharmacokinetics and safety profile of single-dose administration of an estrogen receptor ?-selective phytoestrogenic (phytoSERM) formulation in perimenopausal and postmenopausal women. Menopause 25:191-196
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
Ho, Jean K; Nation, Daniel A; Alzheimer’s Disease Neuroimaging Initiative (2018) Neuropsychological Profiles and Trajectories in Preclinical Alzheimer's Disease. J Int Neuropsychol Soc 24:693-702
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Crum, Jana; Wilson, Jeffrey; Sabbagh, Marwan (2018) Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer's dementia? Alzheimers Res Ther 10:104
Tse, Kai-Hei; Cheng, Aifang; Ma, Fulin et al. (2018) DNA damage-associated oligodendrocyte degeneration precedes amyloid pathology and contributes to Alzheimer's disease and dementia. Alzheimers Dement 14:664-679
Burke, Shanna L; Cadet, Tamara; Maddux, Marlaina (2018) Chronic Health Illnesses as Predictors of Mild Cognitive Impairment Among African American Older Adults. J Natl Med Assoc 110:314-325

Showing the most recent 10 out of 590 publications